Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 2
1986 2
1996 2
1997 1
2004 2
2005 6
2006 3
2007 6
2008 8
2009 5
2010 3
2011 3
2012 2
2013 4
2014 8
2015 9
2016 7
2017 6
2018 6
2019 4
2020 5
2021 6
2022 3
2023 3
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.
Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Bac NH, Cha BK, Imamura T, Sonoyama T, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, Mukae H. Yotsuyanagi H, et al. Among authors: tsuge y. JAMA Netw Open. 2024 Feb 5;7(2):e2354991. doi: 10.1001/jamanetworkopen.2023.54991. JAMA Netw Open. 2024. PMID: 38335000 Free PMC article. Clinical Trial.
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.
Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, Ichihashi G, Sanaki T, Baba K, Tsuge Y, Uehara T. Mukae H, et al. Among authors: tsuge y. Clin Infect Dis. 2023 Apr 17;76(8):1403-1411. doi: 10.1093/cid/ciac933. Clin Infect Dis. 2023. PMID: 36477182 Free PMC article. Clinical Trial.
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Fukuhara T, Ichihashi G, Sanaki T, Baba K, Takeda Y, Tsuge Y, Uehara T. Mukae H, et al. Among authors: tsuge y. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0069722. doi: 10.1128/aac.00697-22. Epub 2022 Sep 13. Antimicrob Agents Chemother. 2022. PMID: 36098519 Free PMC article. Clinical Trial.
A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, Mukae H. Yotsuyanagi H, et al. Among authors: tsuge y. Medicine (Baltimore). 2023 Feb 22;102(8):e33024. doi: 10.1097/MD.0000000000033024. Medicine (Baltimore). 2023. PMID: 36827007 Free PMC article. Clinical Trial.
Design of Wall-Destructive but Membrane-Compatible Solvents.
Kuroda K, Satria H, Miyamura K, Tsuge Y, Ninomiya K, Takahashi K. Kuroda K, et al. Among authors: tsuge y. J Am Chem Soc. 2017 Nov 15;139(45):16052-16055. doi: 10.1021/jacs.7b08914. Epub 2017 Oct 10. J Am Chem Soc. 2017. PMID: 28985068
As(iii) removal through catalytic oxidation and Fe(iii) precipitation.
Oshima K, Kondo H, Konishi E, Yamamoto T, Tsuge Y, Watanabe T, Kishida M. Oshima K, et al. Among authors: tsuge y. RSC Adv. 2022 Jun 7;12(26):16843-16846. doi: 10.1039/d2ra02537j. eCollection 2022 Jun 1. RSC Adv. 2022. PMID: 35754909 Free PMC article.
98 results